Revvity
Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments.
Latest Content
Product News
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
Revvity launches the IDS i20™ platform, automating chemiluminescence immunoassays for multiple diagnostic specialties, increasing throughput and flexibility.
Listicle
RNA Therapeutics: Four Key Modalities Reshaping Medicine
This listicle explores four major RNA therapeutic modalities, highlighting their breakthroughs, challenges and future potential.
Industry Insight
Shaping the Future of Newborn Screening
Dr. Madhuri Hegde discusses Revvity's role in the Generation Study, an ambitious initiative that will sequence the genomes of 100,000 newborns.
Product News
Watchmaker Genomics and Revvity Team To Automate and Streamline NGS Library Preparation
Watchmaker Genomics has collaborated with Revvity to automate its DNA and RNA library preparation kits for NGS workflows on the Sciclone™ G3 NGSx platform.
Product News
Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery
Signals One spans the entire “Design-Make-Test-Decide” R&D lifecycle and empowers researchers to address previously “undruggable” targets.
Product News
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases.
Product News
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England
Revvity has signed an agreement with Genomics England to provide DNA sequencing services for the Generation Study, a project aimed at screening 100,000 newborns for rare genetic disorders.
Product News
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus.
Infographic
Decoding Rare Diseases: How Genomics Is Transforming Diagnosis
This infographic explores how genomic technologies are enabling earlier and more precise diagnoses for patients.
Product News
Revvity Ignites Scientific Breakthroughs at SLAS2025
Revvity, Inc. is set to unveil its new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29.
Advertisement
